China News Agency, Beijing, August 18 (Reporter Sun Zifa) In response to the recent online information about the domestically-made new crown vaccine patent approval, the State Intellectual Property Office of China announced on the 18th, confirming the "Chen Wei team of the Academy of Military Sciences" It is true that the new crown vaccine patent application filed jointly with CanSino Bio has been granted a patent." This invention patent application enjoys a priority review policy.
According to the State Intellectual Property Office, upon verification, the name of the vaccine patent application is "a recombinant new coronavirus vaccine using human replication-deficient adenovirus as a vector", the patent application number is 202010193587.8, and the applicant is the PLA Academy of Military Sciences Military Medical Research Institute and Kansino Biological Co., Ltd. The inventor is Chen Wei, etc., and the application date is March 18, 2020. After submitting a priority review request, the State Intellectual Property Office issued a patent authorization notice on August 11, 2020 After the applicant goes through the patent registration procedures in accordance with the law, the bureau will announce the authorization of the patent.
The State Intellectual Property Office pointed out that the new crown vaccine invention patent application enjoys a priority review policy. Since the outbreak of the new crown pneumonia epidemic, the State Intellectual Property Office has attached great importance to the support of patent examination services for epidemic prevention and control and response. On February 15, 2020, the State Administration for Market Regulation, the State Food and Drug Administration, and the State Intellectual Property Office jointly issued the "Ten Articles for Supporting the Resumption of Work and Production", of which Article 3 stipulates that patent applications and trademark registrations related to the prevention and treatment of new coronary pneumonia are required. Priority review will be granted upon request.
At the same time, the State Intellectual Property Office deals with various patent applications or cases involving the prevention and treatment of new coronary pneumonia, such as new coronary pneumonia treatment and preventive drugs and vaccines, testing methods and instruments, masks, goggles, disinfectants and other protective products and methods, etc. Carry out priority reviews upon request. The content of the patent application relates to the prevention and control technology of the new crown pneumonia epidemic, which belongs to the situation that can be given priority examination as stipulated in the "Administrative Measures for Patent Priority Examination", and it also complies with the relevant provisions of the "Resumption of Work and Production". After the applicant submits a priority review request, the State Intellectual Property Office considers that it meets the priority review criteria and handles it in accordance with the priority review procedure.
The State Intellectual Property Office stated that for all patent applications related to the prevention and control of the new crown pneumonia epidemic, the office strictly implements the policy and gives priority review and support in a fair and impartial manner. (Finish)